Tobias Pindel, Susanne Brandstetter, Wolfgang Sieber, Michael Kabesch M.D.
{"title":"COVID-19 疫苗的过敏皮肤点刺试验及其对改善疫苗接种准备和减少焦虑的贡献","authors":"Tobias Pindel, Susanne Brandstetter, Wolfgang Sieber, Michael Kabesch M.D.","doi":"10.1007/s40629-024-00296-7","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>When coronavirus disease 2019 (COVID-19) vaccines were introduced, they were suspected of triggering severe allergic reactions disproportionately often. This contributed to the fear of vaccination, particularly among allergy patients.</p><h3>Methods</h3><p>In an allergy center in eastern Bavaria, we used a skin prick test to investigate how often sensitization to COVID-19 vaccines can be detected and whether appropriate testing could significantly reduce the fear of vaccination.</p><h3>Results</h3><p>Comirnaty® (<i>n</i> <i>=</i> 245 tested/6.93% <i>clearly positive </i>reaction; Biontec/Pfizer, Mainz, Germany/New York City, NY, USA), Spikevax® (56/14.28%; Moderna, Cambridge, MA, USA), Vaxzevria® (208/4.32%; Astra Zeneca, Cambridge, England) and Jcovden® (48/4.16%; Johnson & Johnson, New Brunswick, NJ, USA) were tested by skin prick test. Most participants tested were female (83.6%) and had a history of allergies (94.8%). Depending on the result of the skin prick test, the test subjects were advised on vaccination. In a questionnaire survey approximately 1 year after testing, 75.7% of the <i>N</i> = 70 respondents stated that their fear of vaccination had been greatly or very greatly reduced as a result of the testing and counseling. In the follow-up survey, 88.5% of all respondents had been vaccinated at least once. No notable allergic problems occurred during the COVID-19 vaccination in study participants.</p><h3>Conclusion</h3><p>The study shows that simple skin prick testing could reduce fears and concerns about allergic reactions to COVID-19 vaccines, and thus significantly increase the willingness to vaccinate in the population, especially among allergy patients.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00296-7.pdf","citationCount":"0","resultStr":"{\"title\":\"Allergy skin prick tests with COVID-19 vaccines and their contribution to improve vaccination readiness and reduce anxiety\",\"authors\":\"Tobias Pindel, Susanne Brandstetter, Wolfgang Sieber, Michael Kabesch M.D.\",\"doi\":\"10.1007/s40629-024-00296-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>When coronavirus disease 2019 (COVID-19) vaccines were introduced, they were suspected of triggering severe allergic reactions disproportionately often. This contributed to the fear of vaccination, particularly among allergy patients.</p><h3>Methods</h3><p>In an allergy center in eastern Bavaria, we used a skin prick test to investigate how often sensitization to COVID-19 vaccines can be detected and whether appropriate testing could significantly reduce the fear of vaccination.</p><h3>Results</h3><p>Comirnaty® (<i>n</i> <i>=</i> 245 tested/6.93% <i>clearly positive </i>reaction; Biontec/Pfizer, Mainz, Germany/New York City, NY, USA), Spikevax® (56/14.28%; Moderna, Cambridge, MA, USA), Vaxzevria® (208/4.32%; Astra Zeneca, Cambridge, England) and Jcovden® (48/4.16%; Johnson & Johnson, New Brunswick, NJ, USA) were tested by skin prick test. Most participants tested were female (83.6%) and had a history of allergies (94.8%). Depending on the result of the skin prick test, the test subjects were advised on vaccination. In a questionnaire survey approximately 1 year after testing, 75.7% of the <i>N</i> = 70 respondents stated that their fear of vaccination had been greatly or very greatly reduced as a result of the testing and counseling. In the follow-up survey, 88.5% of all respondents had been vaccinated at least once. No notable allergic problems occurred during the COVID-19 vaccination in study participants.</p><h3>Conclusion</h3><p>The study shows that simple skin prick testing could reduce fears and concerns about allergic reactions to COVID-19 vaccines, and thus significantly increase the willingness to vaccinate in the population, especially among allergy patients.</p></div>\",\"PeriodicalId\":37457,\"journal\":{\"name\":\"Allergo Journal International\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s40629-024-00296-7.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergo Journal International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40629-024-00296-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergo Journal International","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s40629-024-00296-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Allergy skin prick tests with COVID-19 vaccines and their contribution to improve vaccination readiness and reduce anxiety
Background
When coronavirus disease 2019 (COVID-19) vaccines were introduced, they were suspected of triggering severe allergic reactions disproportionately often. This contributed to the fear of vaccination, particularly among allergy patients.
Methods
In an allergy center in eastern Bavaria, we used a skin prick test to investigate how often sensitization to COVID-19 vaccines can be detected and whether appropriate testing could significantly reduce the fear of vaccination.
Results
Comirnaty® (n= 245 tested/6.93% clearly positive reaction; Biontec/Pfizer, Mainz, Germany/New York City, NY, USA), Spikevax® (56/14.28%; Moderna, Cambridge, MA, USA), Vaxzevria® (208/4.32%; Astra Zeneca, Cambridge, England) and Jcovden® (48/4.16%; Johnson & Johnson, New Brunswick, NJ, USA) were tested by skin prick test. Most participants tested were female (83.6%) and had a history of allergies (94.8%). Depending on the result of the skin prick test, the test subjects were advised on vaccination. In a questionnaire survey approximately 1 year after testing, 75.7% of the N = 70 respondents stated that their fear of vaccination had been greatly or very greatly reduced as a result of the testing and counseling. In the follow-up survey, 88.5% of all respondents had been vaccinated at least once. No notable allergic problems occurred during the COVID-19 vaccination in study participants.
Conclusion
The study shows that simple skin prick testing could reduce fears and concerns about allergic reactions to COVID-19 vaccines, and thus significantly increase the willingness to vaccinate in the population, especially among allergy patients.
期刊介绍:
Allergo Journal International is the official Journal of the German Society for Applied Allergology (AeDA) and the Austrian Society for Allergology and Immunology (ÖGAI). The journal is a forum for the communication and exchange of ideas concerning the various aspects of allergy (including related fields such as clinical immunology and environmental medicine) and promotes German allergy research in an international context. The aim of Allergo Journal International is to provide state of the art information for all medical and scientific disciplines that deal with allergic, immunological and environmental diseases. Allergo Journal International publishes original articles, reviews, short communications, case reports, and letters to the editor. The articles cover topics such as allergic, immunological and environmental diseases, the latest developments in diagnosis and therapy as well as current research work concerning antigens and allergens and aspects related to occupational and environmental medicine. In addition, it publishes clinical guidelines and position papers approved by expert panels of the German, Austrian and Swiss Allergy Societies.
All submissions are reviewed in single-blind fashion by at least two reviewers.
Originally, the journal started as a German journal called Allergo Journal back in 1992. Throughout the years, English articles amounted to a considerable portion in Allergo Journal. This was one of the reasons to extract the scientific content and publish it in a separate journal. Hence, Allergo Journal International was born and now is the international continuation of the original German journal. Nowadays, all original content is published in Allergo Journal International first. Later, selected manuscripts will be translated and published in German and included in Allergo Journal.